SHYNDEC(SH:600420) 智通财经网·2025-09-01 09:47Core Viewpoint - China National Pharmaceutical Group Modern (国药现代) announced that its wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd. (国药容生), has received the drug registration certificate for injectable Nicorandil from the National Medical Products Administration, which is primarily used for treating unstable angina pectoris [1] Group 1 - The approval of the drug registration certificate signifies that the product has passed the consistency evaluation, enhancing the company's product portfolio in the cardiovascular field [1] - This development is expected to strengthen the company's overall market competitiveness in related medication areas [1] - The impact of this approval on the company's current operating performance is not expected to be significant [1]